RT3 (Retatrutide)
LY3437943 · Triple G Receptor Agonist
This research guide covers the triple receptor mechanism, research applications and available sizes — the most advanced multi-receptor agonist research compound currently available, with simultaneous GLP-1, GIP and Glucagon receptor activation in a single research protocol.
What Is RT3?
RT3 (LY3437943) is a synthetic triple receptor agonist research compound targeting three distinct metabolic receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR).
Developed by Eli Lilly and Company, this compound represents the current frontier of incretin-based metabolic research. Its triple receptor profile distinguishes it from first and second generation GLP-1 research compounds, as detailed in peer-reviewed pharmacology literature, enabling scientists to study the combined and potentially synergistic effects of three interconnected metabolic signalling pathways in a single experimental protocol.
Pyrox Labs supplies it as a lyophilised research compound in 10mg and 20mg vials. All compounds are analytical grade with COA available on request.
Research Use Only: RT3 is supplied exclusively for in vitro laboratory research and independent scientific study. Not for human consumption or therapeutic use.
Mechanism of Action
This compound activates three G protein-coupled receptors (GPCRs) with distinct tissue expression patterns, enabling multi-pathway research that is not possible with mono or dual agonist compounds. Researchers can use a single vial to study three interconnected metabolic signalling systems side by side, rather than running separate protocols with three different mono-agonist compounds.
Comparing Triple, Dual And Single Agonism
This compound adds glucagon receptor co-activation to the dual GLP-1/GIP profile of TZ2. The glucagon receptor is expressed primarily in hepatocytes and plays a key role in hepatic glucose output and energy expenditure signalling — pathways not directly studied with GLP-1 or GLP-1/GIP compounds alone. This makes it the most complex and versatile multi-pathway metabolic research compound currently available from Pyrox Labs.
RT3 Research Guide — Applications
Because this compound activates three receptor pathways at once, it supports a wider range of comparative and mechanistic research protocols than single or dual agonist alternatives — some of the most common application areas are outlined below.
Sizes & Pricing
Full sizing and reconstitution details are below. All pricing subject to confirmation.
Storage & Reconstitution
Store lyophilised RT3 at room temperature away from direct light and moisture. Once reconstituted with bacteriostatic water, store refrigerated at 2–8°C and use within 28 days. Do not freeze reconstituted solution.
Full Reconstitution Guide →Buy RT3 UK
Pyrox Labs supplies analytical-grade RT3 for independent research. UK registered, discreet dispatch, 48 hours.
Research Use Only: RT3 supplied by Pyrox Labs is intended exclusively for in vitro laboratory research and independent scientific study. Not a licensed medicine. Not for human consumption, self-administration or therapeutic use. Pyrox Labs provides no medical advice.
